Provided by Tiger Trade Technology Pte. Ltd.

crane

188.46
+1.891.01%
Post-market: 188.460.00000.00%16:10 EDT
Volume:389.03K
Turnover:73.22M
Market Cap:10.85B
PE:30.16
High:189.99
Open:188.02
Low:186.59
Close:186.57
52wk High:214.31
52wk Low:135.47
Shares:57.60M
Float Shares:48.76M
Volume Ratio:0.70
T/O Rate:0.80%
Dividend:0.92
Dividend Rate:0.49%
EPS(TTM):6.25
EPS(LYR):6.26
ROE:17.91%
ROA:7.88%
PB:5.27
PE(LYR):30.13

Loading ...

Crane Co: Assumptions for FY Guidance Include Total Sales Growth of About 7.5%

THOMSON REUTERS
·
Oct 28, 2025

Crane Company Q3 Adj EPS From Continuing Operations $1.64

THOMSON REUTERS
·
Oct 28, 2025

Crane Company Outlook FY Adjusted EPS USD 5.75-5.95

THOMSON REUTERS
·
Oct 28, 2025

Scott Bessent Warns Military Pay At Risk By Mid November Amid Shutdown: 'What An Embarrassment'

Benzinga_recent_news
·
Oct 27, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

GlobeNewswire
·
Oct 25, 2025

Can Crane's (CR) Recent Sales Slump Reshape Expectations for Margin Expansion?

Simply Wall St.
·
Oct 23, 2025

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

GlobeNewswire
·
Oct 21, 2025

Moody's Confirms ICBC Macau's "A2" Long-term Deposits Rating with a "Stable" Outlook

Deep News
·
Oct 21, 2025

Crane (CR): Assessing Valuation Following Declining Sales and Slower Organic Revenue Growth

Simply Wall St.
·
Oct 21, 2025

Why Is Genmab Stock Trading Lower On Monday?

Benzinga_recent_news
·
Oct 20, 2025

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

prnewswire
·
Oct 20, 2025

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

GlobeNewswire
·
Oct 18, 2025

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

GlobeNewswire
·
Oct 18, 2025

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

GlobeNewswire
·
Oct 17, 2025

Clean Energy Technologies, Inc. Advances Vermont Renewable Gas Project to Deliver Clean Power from Agricultural

GlobeNewswire
·
Oct 16, 2025

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

GlobeNewswire
·
Oct 13, 2025